Vaccination-induced skin-resident memory CD8⁺ T cells mediate strong protection against cutaneous melanoma

References

• Prickett TD, Crystal JS, Cohen CJ, Pasetto A, Parkhurst MR, Gartner JJ, Yao X, Wang R, Gros A, Li YF, et al. Durable complete response from metastatic melanoma after transfer of autologous t cells recognizing 10 mutated tumor antigens. Cancer Immunol Res. 2016;4(8):669–78. doi:10.1158/2326-6066.CIR-15-0215. PMID:27312342.
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725–33. doi:10.1056/NEJMoa1103849. PMID:21830940.
   PubMed Web of Science ®Google Scholar
• Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, et al. Chimeric antigen receptor t cells against cd19 for multiple myeloma. N Engl J Med. 2015;373(11):1040–7. doi:10.1056/NEJMoa1504542. PMID:26352815.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, et al. chemotherapy-refractory diffuse large b-cell lymphoma and indolent b-cell malignancies can be effectively treated with autologous t cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540–9. doi:10.1200/JCO.2014.56.2025. PMID:25154820.
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28. doi:10.1056/NEJMoa1501824. PMID:25891174.
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134–44. doi:10.1056/NEJMoa1305133. PMID:23724846.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. doi:10.1056/NEJMoa1003466. PMID:20525992.
   PubMed Web of Science ®Google Scholar
• Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222–6. doi:10.1038/nature23003. PMID:28678784.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217–21. doi:10.1038/nature22991. PMID:28678778.
   PubMed Web of Science ®Google Scholar
• Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364(22):2119–27. doi:10.1056/NEJMoa1012863. PMID:21631324.
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev. 2006;211:214–24. doi:10.1111/j.0105-2896.2006.00391.x. PMID:16824130.
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401(6754):708–12. doi:10.1038/44385. PMID:10537110.
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, Palmer DC, Antony PA, Hwang ST, Rosenberg SA, et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A. 2005;102(27):9571–6. doi:10.1073/pnas.0503726102. PMID:15980149.
   PubMed Web of Science ®Google Scholar
• Park CO, Kupper TS. The emerging role of resident memory T cells in protective immunity and inflammatory disease. Nat Med. 2015;21(7):688–97. doi:10.1038/nm.3883. PMID:26121195.
   PubMed Web of Science ®Google Scholar
• Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, Carbone FR. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat Immunol. 2009;10(5):524–30. doi:10.1038/ni.1718. PMID:19305395.
   PubMed Web of Science ®Google Scholar
• Mackay LK, Rahimpour A, Ma JZ, Collins N, Stock AT, Hafon ML, Vega-Ramos J, Lauzurica P, Mueller SN, Stefanovic T, et al. The developmental pathway for CD103(+)CD8+ tissue-resident memory T cells of skin. Nat Immunol. 2013;14(12):1294–301. doi:10.1038/ni.2744. PMID:24162776.
   PubMed Web of Science ®Google Scholar
• Skon CN, Lee JY, Anderson KG, Masopust D, Hogquist KA, Jameson SC. Transcriptional downregulation of S1pr1 is required for the establishment of resident memory CD8+ T cells. Nat Immunol. 2013;14(12):1285–93. doi:10.1038/ni.2745. PMID:24162775.
   PubMed Web of Science ®Google Scholar
• Jiang X, Clark RA, Liu L, Wagers AJ, Fuhlbrigge RC, Kupper TS. Skin infection generates non-migratory memory CD8+ T(RM) cells providing global skin immunity. Nature. 2012;483(7388):227–31. doi:10.1038/nature10851. PMID:22388819.
   PubMed Web of Science ®Google Scholar
• Ariotti S, Hogenbirk MA, Dijkgraaf FE, Visser LL, Hoekstra ME, Song JY, Jacobs H, Haanen JB, Schumacher TN. T cell memory. Skin-resident memory CD8(+) T cells trigger a state of tissue-wide pathogen alert. Science. 2014;346(6205):101–5. doi:10.1126/science.1254803. PMID:25278612.
   PubMed Web of Science ®Google Scholar
• Schenkel JM, Fraser KA, Vezys V, Masopust D. Sensing and alarm function of resident memory CD8(+) T cells. Nat Immunol. 2013;14(5):509–13. doi:10.1038/ni.2568. PMID:23542740.
   PubMed Web of Science ®Google Scholar
• Zens KD, Chen JK, Farber DL. Vaccine-generated lung tissue-resident memory T cells provide heterosubtypic protection to influenza infection. JCI Insight. 2016;1(10) pii:e85832. doi:10.1172/jci.insight.85832. PMID:27468427.
   PubMed Web of Science ®Google Scholar
• Davies B, Prier JE, Jones CM, Gebhardt T, Carbone FR, Mackay LK. Cutting edge: tissue-resident memory t cells generated by multiple immunizations or localized deposition provide enhanced immunity. J Immunol. 2017;198(6):2233–7. doi:10.4049/jimmunol.1601367. PMID:28159905.
   PubMed Web of Science ®Google Scholar
• Webb JR, Milne K, Watson P, Deleeuw RJ, Nelson BH. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res. 2014;20(2):434–44. doi:10.1158/1078-0432.CCR-13-1877. PMID:24190978.
   PubMed Web of Science ®Google Scholar
• Webb JR, Wick DA, Nielsen JS, Tran E, Milne K, McMurtrie E, Nelson BH. Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (alphaE/beta7 Integrin) in high-grade serous ovarian cancer. Gynecol Oncol. 2010;118(3):228–36. doi:10.1016/j.ygyno.2010.05.016. PMID:20541243.
   PubMed Web of Science ®Google Scholar
• Webb JR, Milne K, Nelson BH. PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer. Cancer Immunol Res. 2015;3(8):926–35. doi:10.1158/2326-6066.CIR-14-0239. PMID:25957117.
   PubMed Web of Science ®Google Scholar
• Wang ZQ, Milne K, Derocher H, Webb JR, Nelson BH, Watson PH. CD103 and Intratumoral Immune Response in Breast Cancer. Clin Cancer Res. 2016;22(24):6290–7. doi:10.1158/1078-0432.CCR-16-0732. PMID:27267849.
   PubMed Web of Science ®Google Scholar
• Djenidi F, Adam J, Goubar A, Durgeau A, Meurice G, de Montpréville V, Validire P, Besse B, Mami-Chouaib F. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J Immunol. 2015;194(7):3475–86. doi:10.4049/jimmunol.1402711. PMID:25725111.
   PubMed Web of Science ®Google Scholar
• Ganesan AP, Clarke J, Wood O, Garrido-Martin EM, Chee SJ, Mellows T, Samaniego-Castruita D, Singh D, Seumois G, Alzetani A, et al. Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. Nat Immunol. 2017;18(8):940–50. doi:10.1038/ni.3775. PMID:28628092.
   PubMed Web of Science ®Google Scholar
• Franciszkiewicz K, Le Floc'h A, Jalil A, Vigant F, Robert T, Vergnon I, Mackiewicz A, Benihoud K, Validire P, Chouaib S, et al. Intratumoral induction of CD103 triggers tumor-specific CTL function and CCR5-dependent T-cell retention. Cancer Res. 2009;69(15):6249–55. doi:10.1158/0008-5472.CAN-08-3571. PMID:19638592.
   PubMed Web of Science ®Google Scholar
• Boutet M, Gauthier L, Leclerc M, Gros G, de Montpreville V, Théret N, Donnadieu E, Mami-Chouaib F. TGFbeta Signaling intersects with CD103 integrin signaling to promote t-lymphocyte accumulation and antitumor activity in the lung tumor microenvironment. Cancer Res. 2016;76(7):1757–69. doi:10.1158/0008-5472.CAN-15-1545. PMID:26921343.
   PubMed Web of Science ®Google Scholar
• Boddupalli CS, Bar N, Kadaveru K, Krauthammer M, Pornputtapong N, Mai Z, Ariyan S, Narayan D, Kluger H, Deng Y, et al. Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells. JCI Insight. 2016;1(21):e88955. doi:10.1172/jci.insight.88955. PMID:28018970.
   PubMed Web of Science ®Google Scholar
• Milner JJ, Toma C, Yu B, Zhang K, Omilusik K, Phan AT, Wang D, Getzler AJ, Nguyen T, Crotty S, et al. Runx3 programs CD8(+) T cell residency in non-lymphoid tissues and tumours. Nature. 2017;552(7684):253–7. PMID:29211713
   PubMed Web of Science ®Google Scholar
• Malik BT, Byrne KT, Vella JL, Zhang P, Shabaneh TB, Steinberg SM, Molodtsov AK, Bowers JS, Angeles CV, Paulos CM, et al. Resident memory T cells in the skin mediate durable immunity to melanoma. Sci Immunol. 2017;2(10) pii:eaam6346. doi:10.1126/sciimmunol.aam6346. PMID:28738020.
   PubMed Web of Science ®Google Scholar
• Enamorado M, Iborra S, Priego E, Cueto FJ, Quintana JA, Martínez-Cano S, Mejías-Pérez E, Esteban M, Melero I, Hidalgo A, et al. Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8+ T cells. Nat Commun. 2017;8:16073. doi:10.1038/ncomms16073. PMID:28714465.
   PubMed Web of Science ®Google Scholar
• Iborra S, Izquierdo HM, Martínez-López M, Blanco-Menéndez N, Reis e Sousa C, Sancho D. The DC receptor DNGR-1 mediates cross-priming of CTLs during vaccinia virus infection in mice. J Clin Invest. 2012;122(5):1628–43. doi:10.1172/JCI60660. PMID:22505455.
   PubMed Web of Science ®Google Scholar
• Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PAet al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010;207(3):637–50. doi:10.1084/jem.20091918. PMID:20156971.
   PubMed Web of Science ®Google Scholar
• Lladser A, Mougiakakos D, Tufvesson H, Ligtenberg MA, Quest AF, Kiessling R, Ljungberg K. DAI (DLM-1/ZBP1) as a genetic adjuvant for DNA vaccines that promotes effective antitumor CTL immunity. Mol Ther. 2011;19(3):594–601. doi:10.1038/mt.2010.268. PMID:21157438.
   PubMed Web of Science ®Google Scholar
• Ligtenberg MA, Witt K, Galvez-Cancino F, Sette A, Lundqvist A, Lladser A, Kiessling R. Cripto-1 vaccination elicits protective immunity against metastatic melanoma. Oncoimmunology. 2016;5(5):e1128613. doi:10.1080/2162402X.2015.1128613. PMID:27467944.
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, Chuang E, Sanborn RE, Lutzky J, Powderly J, et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med. 2014;6(232):232ra51. doi:10.1126/scitranslmed.3008068. PMID:24739759.
   PubMed Web of Science ®Google Scholar
• Idoyaga J, Lubkin A, Fiorese C, Lahoud MH, Caminschi I, Huang Y, Rodriguez A, Clausen BE, Park CG, Trumpfheller C, et al. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9 A. Proc Natl Acad Sci U S A. 2011;108(6):2384–9. doi:10.1073/pnas.1019547108. PMID:21262813.
   PubMed Web of Science ®Google Scholar
• Kadoki M, Patil A, Thaiss CC, Brooks DJ, Pandey S, Deep D, Alvarez D, von Andrian UH, Wagers AJ, Nakai K, et al. Organism-Level Analysis of Vaccination Reveals Networks of Protection across Tissues. Cell. 2017;171(2):398–413 e21. doi:10.1016/j.cell.2017.08.024. PMID:28942919.
   PubMed Web of Science ®Google Scholar
• Ariotti S, Beltman JB, Chodaczek G, Hoekstra ME, van Beek AE, Gomez-Eerland R, Ritsma L, van Rheenen J, Marée AF, Zal T, et al. Tissue-resident memory CD8+ T cells continuously patrol skin epithelia to quickly recognize local antigen. Proc Natl Acad Sci U S A. 2012;109(48):19739–44. doi:10.1073/pnas.1208927109. PMID:23150545.
   PubMed Web of Science ®Google Scholar
• Bergsbaken T, Bevan MJ. Proinflammatory microenvironments within the intestine regulate the differentiation of tissue-resident CD8(+) T cells responding to infection. Nat Immunol. 2015;16(4):406–14. doi:10.1038/ni.3108. PMID:25706747.
   PubMed Web of Science ®Google Scholar
• Idoyaga J, Cheong C, Suda K, Suda N, Kim JY, Lee H, Park CG, Steinman RM. Cutting edge: langerin/CD207 receptor on dendritic cells mediates efficient antigen presentation on MHC I and II products in vivo. J Immunol. 2008;180(6):3647–50. doi:10.4049/jimmunol.180.6.3647. PMID:18322168.
   PubMed Web of Science ®Google Scholar
• Anderson KG, Mayer-Barber K, Sung H, Beura L, James BR, Taylor JJ, Qunaj L, Griffith TS, Vezys V, Barber DL, et al. Intravascular staining for discrimination of vascular and tissue leukocytes. Nat Protoc. 2014;9(1):209–22. doi:10.1038/nprot.2014.005. PMID:24385150.
   PubMed Web of Science ®Google Scholar
• Gebhardt T, Whitney PG, Zaid A, Mackay LK, Brooks AG, Heath WR, Carbone FR, Mueller SN. Different patterns of peripheral migration by memory CD4+ and CD8+ T cells. Nature. 2011;477(7363):216–9. doi:10.1038/nature10339. PMID:21841802.
   PubMed Web of Science ®Google Scholar
• Clark RA, Watanabe R, Teague JE, Schlapbach C, Tawa MC, Adams N, Dorosario AA, Chaney KS, Cutler CS, Leboeuf NR, et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med. 2012;4(117):117ra7. doi:10.1126/scitranslmed.3003008. PMID:22261031.
   PubMed Web of Science ®Google Scholar
• Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004;427(6972):355–60. doi:10.1038/nature02284. PMID:14737169.
   PubMed Web of Science ®Google Scholar
• Li MH, Hla T, Ferrer F. FTY720 inhibits tumor growth and enhances the tumor-suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway. Pediatr Blood Cancer. 2013;60(9):1418–23. doi:10.1002/pbc.24564. PMID:23704073.
   PubMed Web of Science ®Google Scholar
• Tsai HC, Huang Y, Garris CS, Moreno MA, Griffin CW, Han MH. Effects of sphingosine-1-phosphate receptor 1 phosphorylation in response to FTY720 during neuroinflammation. JCI Insight. 2016;1(9):e86462. doi:10.1172/jci.insight.86462. PMID:27699272.
   PubMed Web of Science ®Google Scholar
• Ntranos A, Hall O, Robinson DP, Grishkan IV, Schott JT, Tosi DM, Klein SL, Calabresi PA, Gocke AR. FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway. J Neuroimmunol. 2014;270(1-2):13–21. doi:10.1016/j.jneuroim.2014.03.007. PMID:24680062.
   PubMed Web of Science ®Google Scholar
• Azuma H, Takahara S, Ichimaru N, Wang JD, Itoh Y, Otsuki Y, Morimoto J, Fukui R, Hoshiga M, Ishihara T, et al. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res. 2002;62(5):1410–9. PMID:11888913
   PubMed Web of Science ®Google Scholar
• Ng KT, Man K, Ho JW, Sun CK, Lee TK, Zhao Y, Lo CM, Poon RT, Fan ST. Marked suppression of tumor growth by FTY720 in a rat liver tumor model: the significance of down-regulation of cell survival Akt pathway. Int J Oncol. 2007;30(2):375–80. PMID:17203219.
   PubMed Web of Science ®Google Scholar
• Thompson ED, Enriquez HL, Fu YX, Engelhard VH. Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med. 2010;207(8):1791–804. doi:10.1084/jem.20092454. PMID:20660615.
   PubMed Web of Science ®Google Scholar
• Wang L, Pino-Lagos K, de Vries VC, Guleria I, Sayegh MH, Noelle RJ. Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci U S A. 2008;105(27):9331–6. doi:10.1073/pnas.0710441105. PMID:18599457.
   PubMed Web of Science ®Google Scholar
• Zhong S, Malecek K, Johnson LA, Yu Z, Vega-Saenz de Miera E, Darvishian F, McGary K, Huang K, Boyer J, Corse E, et al. T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proc Natl Acad Sci U S A. 2013;110(17):6973–8. doi:10.1073/pnas.1221609110. PMID:23576742.
   PubMed Web of Science ®Google Scholar
• Frost EL, Kersh AE, Evavold BD, Lukacher AE. Cutting Edge: Resident Memory CD8 T Cells Express High-Affinity TCRs. J Immunol. 2015;195(8):3520–4. doi:10.4049/jimmunol.1501521. PMID:26371252.
   PubMed Web of Science ®Google Scholar
• Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003;198(4):569–80. doi:10.1084/jem.20030590. PMID:12925674.
   PubMed Web of Science ®Google Scholar
• Stone JD, Harris DT, Kranz DM. TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity. Curr Opin Immunol. 2015;33:16–22. doi:10.1016/j.coi.2015.01.003. PMID:25618219.
   PubMed Web of Science ®Google Scholar
• Badou A, Savignac M, Moreau M, Leclerc C, Foucras G, Cassar G, Paulet P, Lagrange D, Druet P, Guéry JC, et al. Weak TCR stimulation induces a calcium signal that triggers IL-4 synthesis, stronger TCR stimulation induces MAP kinases that control IFN-gamma production. Eur J Immunol. 2001;31(8):2487–96. doi:10.1002/1521-4141(200108)31:8%3c2487::AID-IMMU2487%3e3.0.CO;2-L. PMID:11500833.
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69–74. doi:10.1126/science.aaa4971. PMID:25838375.
   PubMed Web of Science ®Google Scholar
• Kim TJ, Jin HT, Hur SY, Yang HG, Seo YB, Hong SR, Lee CW, Kim S, Woo JW, Park KS, et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nat Commun. 2014;5:5317. doi:10.1038/ncomms6317. PMID:25354725.
   PubMed Web of Science ®Google Scholar
• Walters JN, Ferraro B, Duperret EK, Kraynyak KA, Chu J, Saint-Fleur A, Yan J, Levitsky H, Khan AS, Sardesai NY, et al. A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity. Mol Ther. 2017;25(4):976–88. doi:10.1016/j.ymthe.2017.01.022. PMID:28237837.
   PubMed Web of Science ®Google Scholar
• Guo C, Manjili MH, Subjeck JR, Sarkar D, Fisher PB, Wang XY. Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res. 2013;119:421–75. doi:10.1016/B978-0-12-407190-2.00007-1. PMID:23870514.
   PubMed Web of Science ®Google Scholar
• Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, Gherardini PF, Prestwood TR, Chabon J, Bendall SC, et al. Systemic Immunity Is Required for Effective Cancer Immunotherapy. Cell. 2017;168(3):487–502 e15. doi:10.1016/j.cell.2016.12.022. PMID:28111070.
   PubMed Web of Science ®Google Scholar
• Enamorado M, Iborra S, Priego E, Cueto FJ, Quintana JA, Martínez-Cano S, Mejías-Pérez E, Esteban M, Melero I, Hidalgo A, et al. Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8(+) T cells. Nat Commun. 2017;8:16073. doi:10.1038/ncomms16073. PMID:28714465.
   PubMed Web of Science ®Google Scholar